Arvinas (ARVN) Cash from Financing Activities (2017 - 2026)
Arvinas' (ARVN) quarterly Cash from Financing Activities came in at -$100000.0 in Q1 2026, little changed year-on-year from -$100000.0 in Q1 2025, and up 99.86% quarter-over-quarter from -$74.0 million in Q4 2025.
Arvinas (ARVN) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Arvinas' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$100000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities changed 0.0% year-over-year to -$100000.0 in Q1 2026; TTM through Mar 2026 was -$91.4 million, a 1574.19% decrease from a year earlier, with the FY2025 full-year figure at -$91.4 million, down 1256.96% from the prior year.
- Cash from Financing Activities grew to -$100000.0 in Q1 2026 per ARVN's latest filing, from -$74.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $334.8 million in Q4 2023 and bottomed at -$74.0 million in Q4 2025.
- The 5-year median for Cash from Financing Activities is $500000.0 (2022), against an average of $17.4 million.
- Across the five-year window, Cash from Financing Activities jumped 66860.0% in 2023 and sank 14900.0% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $500000.0 in 2022, then soared by 66860.0% to $334.8 million in 2023, then plunged by 99.85% to $500000.0 in 2024, then sank by 14900.0% to -$74.0 million in 2025, then surged by 99.86% to -$100000.0 in 2026.
- Per Business Quant, the three latest ARVN Cash from Financing Activities figures stand at -$100000.0 (Q1 2026), -$74.0 million (Q4 2025), and -$17.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100,000.00 |
| Mar 31, 2026 | -100,000.00 |
| Dec 31, 2025 | -74.00 Mn |
| Dec 31, 2025 | -74.00 Mn |
| Sep 30, 2025 | -17.80 Mn |
| Sep 30, 2025 | -17.80 Mn |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 334.80 Mn |
| Dec 31, 2023 | 334.80 Mn |